<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260912071019N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-13</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Philos plate vs 3.5 distal medial plate in humerus fractures</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of surgical outcomes of distal one-third humerus fractures using Philos plate versus a 3.5 distal medial plate: A Randomized controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-14</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/93241</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Factorial, Purpose: Treatment, Randomization description: Participants will be individually randomized in a 1:1 ratio into two treatment groups using simple randomization. Group A will receive fixation with two PHILOS plates, while Group B will receive fixation with a 3.5-mm distal medial tibial locking plate adapted for use in distal-third humeral fractures.

The randomization sequence will be generated using a computer-generated random sequence, with each eligible participant assigned to either Group A or Group B according to the generated sequence. No stratification or clustering will be used.

Allocation concealment will be maintained until the time of treatment allocation. The randomization sequence will not be disclosed to the investigators responsible for patient assessment before allocation.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Distal one-third humeral fractures.</hc_freetext>
      <i_freetext>Intervention group 1: Patients will undergo open reduction and internal fixation of acute extra-articular distal one-third humeral fractures using two PHILOS (Proximal Humeral Internal Locking System) plates in an orthogonal 90°–90° configuration. Intervention group 2: Patients will undergo open reduction and internal fixation using a 3.5-mm distal medial tibial locking plate adapted for fixation of the distal one-third of the humerus.Both groups will receive standard postoperative care and will be clinically and radiographically followed at 2, 6, and 12 months after surgery. Outcomes will include functional status, pain, elbow range of motion, fracture alignment and union, fixation stability, and postoperative complications..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
De-identified Individual Participant Data__Philos vs median distal plate 

The dataset will include de-identified individual participant data collected during the study, including demographic characteristics, treatment group allocation, pain scores, Disabilities of the Arm, Shoulder and Hand (DASH) scores, elbow range of motion, radiographic fracture healing and alignment, fixation stability, and postoperative complications. Direct personal identifiers will be removed before sharing. The shared dataset will contain data necessary to reproduce or further analyze the study outcomes while protecting participant confidentiality.

When:
The de-identified individual participant data will become available 6 months after publication of the study results and will remain available for 5 years thereafter.

To whom:
The de-identified individual participant data (IPD) and supporting study documents will be available to researchers and investigators from academic institutions, research organizations, healthcare institutions, and other organizations, including non-academic or commercial organizations, upon reasonable request. Access will be provided for scientifically and ethically appropriate purposes, subject to protection of participant confidentiality and applicable ethical and institutional requirements.

Conditions:
De-identified individual participant data (IPD) and supporting study documents may be shared upon reasonable request for scientifically and ethically appropriate purposes, including secondary analyses, methodological research, replication of the study findings, and systematic reviews or meta-analyses. Requests should include a brief description of the proposed research question, analysis plan, and intended use of the data. Requests will be reviewed by the principal investigator and, when necessary, the relevant institutional ethics authorities. Data will be provided only when the proposed use is consistent with participant consent, applicable ethical requirements, and protection of confidentiality. No attempt to re-identify individual participants will be permitted.

Where to obtain:
The de-identified individual participant data and supporting study documents will be obtainable from the research team at Alzahra Tertiary Care Center, affiliated with Isfahan University of Medical Sciences, Isfahan, Iran. Researchers interested in accessing the data should contact the principal investigator, Dr. Mohammad Parhamfar, through the institutional contact details provided by Isfahan University of Medical Sciences. Requests may also be submitted through the corresponding institutional research or ethics office. Data access will be subject to the criteria specified for data use, protection of participant confidentiality, and applicable institutional and ethical requirements.

How to obtain:
Researchers wishing to access the de-identified individual participant data (IPD) or supporting study documents should submit a written request to the principal investigator, Dr. Mohammad Parhamfar, through the institutional contact details provided by Isfahan University of Medical Sciences. The request should briefly describe the research purpose, proposed analyses, and intended use of the requested data.

The research team will review the request for scientific appropriateness, ethical considerations, compatibility with participant consent, and protection of confidentiality. If additional institutional or ethical approval is required, the applicant will be informed and asked to provide the relevant documentation.

Requests will generally be reviewed within 30 days of receipt of a complete request. Following approval, the de-identified data or requested documents will be prepared and securely provided to the applicant, generally within an additional 15 days. The total process is therefore expected to take approximately 30–45 days, depending on the complexity of the request and any required institutional or ethical review.

No directly identifying information will be provided, and data will be shared only in accordance with the approved data-use criteria and applicable ethical and institutional requirements.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Parhamfar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isfahan, Hezar Jerib Avenue, JM76+5M3 Isfahan University</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۱۷۴۶۷۳۴۴۱</zip>
        <telephone>+98 913 308 6821</telephone>
        <email>parhamfar@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Parhamfar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isfahan, Hezar Jerib Avenue, JM76+5M3 Isfahan University</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۱۷۴۶۷۳۴۴۱</zip>
        <telephone>+98 913 308 6821</telephone>
        <email>parhamfar@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Adults aged 18 years or older.
Patients with an acute, isolated fracture of the distal one-third of the humeral shaft confirmed by radiographic evaluation.
Extra-articular distal-third humeral fractures requiring operative fixation.
Patients who provide written informed consent to participate in the study.
Patients who are medically eligible for surgical treatment.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Patients with open fractures or fractures associated with significant soft-tissue injury.
2. Pathological fractures or fractures associated with an underlying bone disease.
3. Intra-articular distal humeral fractures.
4. Associated fractures of the ipsilateral upper limb that may affect functional assessment.
5. Pre-existing neurological or musculoskeletal disorders affecting the function or range of motion of the affected upper limb.
6. Associated neurovascular injuries requiring additional surgical intervention.
7. Patients with a history of previous surgery or significant trauma to the affected humerus or elbow.
8. Patients with severe medical comorbidities or contraindications to surgery or anesthesia.
9. Patients unwilling or unable to provide informed consent or comply with the scheduled follow-up assessments.
10. Patients who withdraw consent or are lost to follow-up during the study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M80.02</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Age-related osteoporosis with current pathological fracture, humerus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Patients will undergo open reduction and internal fixation of acute extra-articular distal one-third humeral fractures using two PHILOS (Proximal Humeral Internal Locking System) plates in an orthogonal 90°–90° configuration. Intervention group 2: Patients will undergo open reduction and internal fixation using a 3.5-mm distal medial tibial locking plate adapted for fixation of the distal one-third of the humerus.Both groups will receive standard postoperative care and will be clinically and radiographically followed at 2, 6, and 12 months after surgery. Outcomes will include functional status, pain, elbow range of motion, fracture alignment and union, fixation stability, and postoperative complications.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The primary outcome variable is the Disabilities of the Arm, Shoulder and Hand (DASH) score, assessed at 12 months after surgery. The DASH score will be used to compare the functional outcome of the affected upper limb between patients treated with two PHILOS plates and those treated with a 3.5-mm distal medial locking plate. Lower DASH scores indicate better upper-limb function. Timepoint: 12 months. Method of measurement: The Disabilities of the Arm, Shoulder and Hand (DASH) score will be measured using the standardized 30-item DASH questionnaire. Participants will complete the questionnaire to assess symptoms and functional limitations of the affected upper limb. The DASH score will be calculated according to the standard scoring method, ranging from 0 to 100, with higher scores indicating greater disability.</prim_outcome>
      <prim_outcome>The Visual Analogue Scale (VAS) pain score will be assessed to compare postoperative pain intensity between the two treatment groups. Pain scores will be evaluated during follow-up and compared between patients treated with two PHILOS plates and those treated with a 3.5-mm distal medial locking plate. Higher VAS scores indicate greater pain intensity. Timepoint: 2, 6, and 12 months after surgery. Method of measurement: Pain intensity will be measured using a Visual Analogue Scale (VAS), with scores ranging from 0 to 10. A score of 0 indicates no pain and a score of 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.</prim_outcome>
      <prim_outcome>Elbow range of motion will be assessed to compare postoperative elbow mobility between the two treatment groups. The range of motion of the affected elbow will be evaluated during follow-up after fixation with either two PHILOS plates or a 3.5-mm distal medial locking plate. Timepoint: 2, 6, and 12 months after surgery. Method of measurement: Elbow range of motion will be measured using a standard goniometer. Flexion, extension, pronation, and supination of the affected upper limb will be assessed and recorded in degrees.</prim_outcome>
      <prim_outcome>Fracture alignment will be assessed to compare the radiographic quality of fracture reduction and maintenance of alignment between the two treatment groups. Alignment of the distal one-third humeral fracture will be evaluated after fixation with two PHILOS plates or a 3.5-mm distal medial locking plate. Timepoint: 2, 6, and 12 months after surgery. Method of measurement: Fracture alignment will be assessed using standard postoperative and follow-up radiographs of the humerus. The radiographs will be evaluated for maintenance of reduction, angular deformity, and displacement of the fracture site.</prim_outcome>
      <prim_outcome>Fracture union will be assessed to compare the radiographic healing of distal one-third humeral fractures between the two treatment groups. The occurrence and timing of fracture union, as well as delayed union or nonunion, will be recorded during follow-up. Timepoint: 2, 6, and 12 months after surgery. Method of measurement: Fracture union will be assessed using serial radiographs of the humerus. Union will be determined based on radiographic evidence of bridging callus and progressive disappearance of the fracture line, together with clinical evidence of fracture healing. The time to union will be recorded in months after surgery.</prim_outcome>
      <prim_outcome>Fixation stability will be assessed to compare the maintenance of implant position and fracture fixation between the two treatment groups. Evidence of loss of fixation, implant displacement, screw loosening, plate failure, or other mechanical complications will be recorded during follow-up. Timepoint: 2, 6, and 12 months after surgery. Method of measurement: Fixation stability will be assessed by clinical examination and serial radiographs of the affected humerus. Radiographs will be evaluated for implant position, loss of reduction, screw loosening or migration, plate deformation or breakage, and other evidence of mechanical failure.</prim_outcome>
      <prim_outcome>Postoperative complications will be assessed to compare the safety profiles of the two fixation methods. Complications of interest include surgical-site infection, neurovascular injury, hardware failure, delayed union, nonunion, and other clinically relevant postoperative complications occurring during follow-up. Timepoint: 2, 6, and 12 months after surgery, with complications recorded throughout the follow-up period. Method of measurement: Postoperative complications will be assessed through clinical examination, review of medical records, and radiographic evaluation when indicated. The presence, type, severity, and timing of complications will be recorded throughout the follow-up period.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-12-27</approval_date>
        <contact_name>Ethics Committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan, Hezar Jerib Avenue, JM76+5M3 Isfahan University Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
